HBOA ameliorates CCl4-incuded liver fibrosis through inhibiting TGF-β1/Smads, NF-κB and ERK signaling pathways

An ingredient was isolated from Acanthus ilicifolius and identified as 4-hydroxy-2(3H)-benzoxazolone (HBOA). Its protective effects and underlying mechanism on liver fibrosis were investigated. Briefly, rats were intragastrically administrated with 50% CCl4 twice a week for 12 weeks to induce liver...

Full description

Bibliographic Details
Main Authors: Xuemei Sun, Xiukun Huang, Xunshuai Zhu, Lin Liu, Siyan Mo, Hongyuan Wang, Xiugui Wei, Shunyu Lu, Facheng Bai, Dandan Wang, Xing Lin, Jun Lin
Format: Article
Language:English
Published: Elsevier 2019-07-01
Series:Biomedicine & Pharmacotherapy
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S075333221930215X
id doaj-a51f7a392d604d24993f0aca000c1801
record_format Article
spelling doaj-a51f7a392d604d24993f0aca000c18012021-05-20T07:37:30ZengElsevierBiomedicine & Pharmacotherapy0753-33222019-07-01115HBOA ameliorates CCl4-incuded liver fibrosis through inhibiting TGF-β1/Smads, NF-κB and ERK signaling pathwaysXuemei Sun0Xiukun Huang1Xunshuai Zhu2Lin Liu3Siyan Mo4Hongyuan Wang5Xiugui Wei6Shunyu Lu7Facheng Bai8Dandan Wang9Xing Lin10Jun Lin11Department of Pharmacology, Guangxi Medical University, Nanning, 530021, ChinaDepartment of Pharmacology, Guangxi Medical University, Nanning, 530021, ChinaDepartment of Pharmacology, Guangxi Medical University, Nanning, 530021, ChinaDepartment of Pharmacology, Guangxi Medical University, Nanning, 530021, ChinaDepartment of Pharmacology, Guangxi Medical University, Nanning, 530021, ChinaDepartment of Pharmacology, Guangxi Medical University, Nanning, 530021, ChinaDepartment of Pharmacology, Guangxi Medical University, Nanning, 530021, ChinaDepartment of Pharmacology, Guangxi Medical University, Nanning, 530021, ChinaDepartment of Pharmacology, Guangxi Medical University, Nanning, 530021, ChinaDepartment of Pharmacology, Guangxi Medical University, Nanning, 530021, ChinaCorresponding authors.; Department of Pharmacology, Guangxi Medical University, Nanning, 530021, ChinaCorresponding authors.; Department of Pharmacology, Guangxi Medical University, Nanning, 530021, ChinaAn ingredient was isolated from Acanthus ilicifolius and identified as 4-hydroxy-2(3H)-benzoxazolone (HBOA). Its protective effects and underlying mechanism on liver fibrosis were investigated. Briefly, rats were intragastrically administrated with 50% CCl4 twice a week for 12 weeks to induce liver fibrosis. Meanwhile, the animals were treated with various medicines from weeks 8 to 12. Then the histological change, serum biochemical index, inflammatory factors and hepatocyte apoptosis were detected. Moreover, the TGF-β1/Smads, NF-κB and ERK signaling pathways were also detected to illustrate the underlying mechanism. The results showed that HBOA significantly ameliorated CCl4-induced liver injury and collagen accumulation in rats, as evidenced by the histopathologic improvement. Moreover, HBOA markedly decreased hepatocyte apoptosis by regulating the expression levels of caspase-3, -9 and -12, as well as the Bcl-2 family. The mechanism study showed that HBOA significantly decreased the expressions of α-smooth muscle actin (α-SMA) and collagen and inhibited the generation of excessive extracellular matrix (ECM) components by restoring the balance between matrix metalloproteinases (MMPs) and its inhibitor (TIMPs). HBOA markedly alleviated oxidative stress and inflammatory cytokines through inhibiting the NF-κB pathway. In addition, HBOA significantly down-regulated the levels of TGF-β1, Smad2/3, Smad4 and up-regulated the level of Smad7, inhibiting the TGF-β1/Smads signaling pathway. Moreover, HBOA significantly blocked the ERK signaling pathway, leading to the inactivation of hepatic stellate cells. This study suggests that HBOA exerts a protective effect against liver fibrosis via modulating the TGF-β1/Smads, NF-κB and ERK signaling pathways, which will be developed as a potential agent for the treatment of liver fibrosis.http://www.sciencedirect.com/science/article/pii/S075333221930215XHepatic fibrosis4-Hydroxy-2(3H)-benzoxazolone (HBOA)TGF-β1/Smads pathwayNF-κB pathwayERK pathwayApoptosis
collection DOAJ
language English
format Article
sources DOAJ
author Xuemei Sun
Xiukun Huang
Xunshuai Zhu
Lin Liu
Siyan Mo
Hongyuan Wang
Xiugui Wei
Shunyu Lu
Facheng Bai
Dandan Wang
Xing Lin
Jun Lin
spellingShingle Xuemei Sun
Xiukun Huang
Xunshuai Zhu
Lin Liu
Siyan Mo
Hongyuan Wang
Xiugui Wei
Shunyu Lu
Facheng Bai
Dandan Wang
Xing Lin
Jun Lin
HBOA ameliorates CCl4-incuded liver fibrosis through inhibiting TGF-β1/Smads, NF-κB and ERK signaling pathways
Biomedicine & Pharmacotherapy
Hepatic fibrosis
4-Hydroxy-2(3H)-benzoxazolone (HBOA)
TGF-β1/Smads pathway
NF-κB pathway
ERK pathway
Apoptosis
author_facet Xuemei Sun
Xiukun Huang
Xunshuai Zhu
Lin Liu
Siyan Mo
Hongyuan Wang
Xiugui Wei
Shunyu Lu
Facheng Bai
Dandan Wang
Xing Lin
Jun Lin
author_sort Xuemei Sun
title HBOA ameliorates CCl4-incuded liver fibrosis through inhibiting TGF-β1/Smads, NF-κB and ERK signaling pathways
title_short HBOA ameliorates CCl4-incuded liver fibrosis through inhibiting TGF-β1/Smads, NF-κB and ERK signaling pathways
title_full HBOA ameliorates CCl4-incuded liver fibrosis through inhibiting TGF-β1/Smads, NF-κB and ERK signaling pathways
title_fullStr HBOA ameliorates CCl4-incuded liver fibrosis through inhibiting TGF-β1/Smads, NF-κB and ERK signaling pathways
title_full_unstemmed HBOA ameliorates CCl4-incuded liver fibrosis through inhibiting TGF-β1/Smads, NF-κB and ERK signaling pathways
title_sort hboa ameliorates ccl4-incuded liver fibrosis through inhibiting tgf-β1/smads, nf-κb and erk signaling pathways
publisher Elsevier
series Biomedicine & Pharmacotherapy
issn 0753-3322
publishDate 2019-07-01
description An ingredient was isolated from Acanthus ilicifolius and identified as 4-hydroxy-2(3H)-benzoxazolone (HBOA). Its protective effects and underlying mechanism on liver fibrosis were investigated. Briefly, rats were intragastrically administrated with 50% CCl4 twice a week for 12 weeks to induce liver fibrosis. Meanwhile, the animals were treated with various medicines from weeks 8 to 12. Then the histological change, serum biochemical index, inflammatory factors and hepatocyte apoptosis were detected. Moreover, the TGF-β1/Smads, NF-κB and ERK signaling pathways were also detected to illustrate the underlying mechanism. The results showed that HBOA significantly ameliorated CCl4-induced liver injury and collagen accumulation in rats, as evidenced by the histopathologic improvement. Moreover, HBOA markedly decreased hepatocyte apoptosis by regulating the expression levels of caspase-3, -9 and -12, as well as the Bcl-2 family. The mechanism study showed that HBOA significantly decreased the expressions of α-smooth muscle actin (α-SMA) and collagen and inhibited the generation of excessive extracellular matrix (ECM) components by restoring the balance between matrix metalloproteinases (MMPs) and its inhibitor (TIMPs). HBOA markedly alleviated oxidative stress and inflammatory cytokines through inhibiting the NF-κB pathway. In addition, HBOA significantly down-regulated the levels of TGF-β1, Smad2/3, Smad4 and up-regulated the level of Smad7, inhibiting the TGF-β1/Smads signaling pathway. Moreover, HBOA significantly blocked the ERK signaling pathway, leading to the inactivation of hepatic stellate cells. This study suggests that HBOA exerts a protective effect against liver fibrosis via modulating the TGF-β1/Smads, NF-κB and ERK signaling pathways, which will be developed as a potential agent for the treatment of liver fibrosis.
topic Hepatic fibrosis
4-Hydroxy-2(3H)-benzoxazolone (HBOA)
TGF-β1/Smads pathway
NF-κB pathway
ERK pathway
Apoptosis
url http://www.sciencedirect.com/science/article/pii/S075333221930215X
work_keys_str_mv AT xuemeisun hboaamelioratesccl4incudedliverfibrosisthroughinhibitingtgfb1smadsnfkbanderksignalingpathways
AT xiukunhuang hboaamelioratesccl4incudedliverfibrosisthroughinhibitingtgfb1smadsnfkbanderksignalingpathways
AT xunshuaizhu hboaamelioratesccl4incudedliverfibrosisthroughinhibitingtgfb1smadsnfkbanderksignalingpathways
AT linliu hboaamelioratesccl4incudedliverfibrosisthroughinhibitingtgfb1smadsnfkbanderksignalingpathways
AT siyanmo hboaamelioratesccl4incudedliverfibrosisthroughinhibitingtgfb1smadsnfkbanderksignalingpathways
AT hongyuanwang hboaamelioratesccl4incudedliverfibrosisthroughinhibitingtgfb1smadsnfkbanderksignalingpathways
AT xiuguiwei hboaamelioratesccl4incudedliverfibrosisthroughinhibitingtgfb1smadsnfkbanderksignalingpathways
AT shunyulu hboaamelioratesccl4incudedliverfibrosisthroughinhibitingtgfb1smadsnfkbanderksignalingpathways
AT fachengbai hboaamelioratesccl4incudedliverfibrosisthroughinhibitingtgfb1smadsnfkbanderksignalingpathways
AT dandanwang hboaamelioratesccl4incudedliverfibrosisthroughinhibitingtgfb1smadsnfkbanderksignalingpathways
AT xinglin hboaamelioratesccl4incudedliverfibrosisthroughinhibitingtgfb1smadsnfkbanderksignalingpathways
AT junlin hboaamelioratesccl4incudedliverfibrosisthroughinhibitingtgfb1smadsnfkbanderksignalingpathways
_version_ 1721435358158127104